Trump reclassifies marijuana. What does that mean for NC, the U.S.?

On Dec. 18 President Trump signed an executive order directing Attorney General Pam Bondi to reclassify marijuana from a Schedule I to a Schedule III substance, initiating federal rulemaking and a push to redefine hemp-derived cannabinoids like CBD. The change would allow cannabis firms access to a Schedule III business-tax break, potentially lower tax burdens, accelerate research and ease access to capital, but interstate sales remain barred absent FDA approval. At the state level, North Carolina remains illegal (decriminalized) aside from industrial hemp and a sovereign Cherokee medical dispensary.

Analysis

Market structure: Reclassifying marijuana to Schedule III materially improves cashflow profiles for federally exposed operators by unlocking a Schedule‑III tax break and lowering cost of capital; expect US multi‑state operators (MSOs) and cannabis real‑estate (IIPR) to see margin expansion of 200–500 bps over 12–24 months if IRS/DEA implement guidance. Competitive dynamics will favor profitable, vertically integrated MSOs with state licenses and U.S. banking access — pricing power shifts to operators with scalable GMP/QA processes because interstate commerce remains closed absent FDA approval.

Risk assessment: Key tail risks include DEA delaying final rulemaking >90–180 days, Congressional reversal, or FDA refusing cross‑state commercialization — each could erase 50–100% of re‑rating. Near‑term (days–weeks) volatility will hinge on rule deadlines and bank/brokerage policy updates; medium term (3–12 months) depends on IRS 280E guidance and capital markets loosening; long term (>12 months) depends on FDA approvals and true interstate commerce.

Trade implications: Direct plays are long US MSOs, IIPR and ancillary growers/retailers; short overlevered Canadian LPs that reliant on full federal legalization (CGC, CRON). Use option structures to express timing: 6–18 month calls on MJ ETF (MJ) and IIPR with stop losses at 20–25% and profit targets at +30–50%.

Contrarian angles: Consensus overprices immediate banking/ interstate upside — the market may underappreciate ancillary winners (SMG) and real‑estate REITs while overpaying large Canadian LPs; historical parallel is 2018 hemp deregulation where supply gluts crushed margins, implying monitor cultivation CAPEX to avoid a similar bust.

Key Decisions for Investors

• Establish a 2–3% long position in Innovative Industrial Properties (IIPR) within 2–6 weeks, target 30–50% upside over 6–12 months; place a 22% stop‑loss and reassess if DEA final rule not published within 90 days.
• Initiate a 3% long allocation to MJ ETF (MJ) via a 12‑month call spread (buy Jan 2026 25% OTM, sell Jan 2026 60% OTM) to capture re‑rating while limiting premium outlay; close if ETF fails to exceed +20% within 4 months.
• Execute a pair trade: long Curaleaf (CURLF) +3% vs short Canopy Growth (CGC) −3% (size neutral) — thesis: US MSO margin expansion vs Canadian LP valuation re‑reset; stop losses at 25% adverse move on either leg.
• Buy short‑dated (3–6 month) calls on Scotts Miracle‑Gro (SMG) sized 1–2% as ancillary/inputs stand to benefit from cultivation capex; exit on a 25–40% rally or if cultivation CAPEX announcements spike supply risk.
• Monitor three binary catalysts closely: DEA rule publication (within 90–180 days), IRS 280E guidance (6–12 months), and any FDA pathway approval (12–36 months); reduce cannabis equities exposure by 50% if any two fail to progress within their windows.